Albert Lobuglio, M.D.
Dr. LoBuglio served as the Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham from March of 1983 through July of 2004. He is currently Director Emeritus and Distinguished Professor as well as Acting Associate Director for Clinical Research in the Comprehensive Cancer Center and leads the Targeted Immunotherapy Group. He has been involved in the field of human tumor immunology for over 25 years and has extensive experience with monoclonal antibodies, monoclonal antibody conjugates, vaccines and early phase clinical trials. He is on the scientific advisory boards of a variety of biotech companies and cancer centers. He major currently responsibilities include the enhancement of translational research activities within the Cancer Center and mentoring of young faculty.

Wells Messersmith, M.D.
Dr. Messersmith joined the UCDHSC faculty in August 2007 as the Director of Gastrointestinal Medical Oncology as well as an active participant in the Drug Development Program. He trained in internal medicine at Massachusetts General Hospital / Harvard Medical School and did his Medical Oncology / Drug Development Fellowship at Johns Hopkins, where he was on the faculty from 2004-2007 as Assistant Professor in the GI Oncology and Drug Development programs.

Dr. Messersmith is focused on clinical and translational cancer research and is the director of the Gastrointestinal (GI) Medical Oncology Program. This comprehensive program includes multi-disciplinary GI cancer clinics, tumor boards, and research endeavors. Dr. Messersmith holds several NIH grants (K23, R21) and is the principal investigator on numerous national and local therapeutic trials. He is an active investigator in the developmental therapeutics laboratory, working on novel targeted therapies as well as correlative studies for use on human tissue samples.